BRINGING THE RIGHT PIECES TOGETHER

Cancer genomic tests that complete the diagnostic picture

We help clinicians give their patients informed answers now and make personalized treatment plans for the future. Through collaborative research and comprehensive test data, we help support advances in precision cancer care.

Explore our cancer tests

Afirma® Thyroid
Decipher® Prostate
Decipher® Bladder
Prosigna® Breast

Latest News

Decipher® Prostate Metastatic Test Now Available for Patients with Metastatic Prostate Cancer in the U.S.

Read More

Developing diagnostics to help more people

Our genomic tests are helping transform cancer care for hundreds of thousands of patients while advancing scientific understanding through collaborative research and clinical evidence generation.

View clinical evidence

>600K

Total patients served with our tests1

>500

Publications utilizing our tests1

Veracyte diagnostics platform

A novel platform for diagnostics

Our Veracyte Diagnostic Platform delivers diagnostic innovation.

  • More data: Broad genomic assays and clinical data
  • More insights: AI-assisted data mining
  • More proof: robust and efficient evidence generation engine
  • More utility: differentiated market expansion approach
Explore our portfolio
A physician and a patient smile while reviewing information together.

Transforming cancer care for patients globally

Our molecular diagnostics empower clinicians with precision insights that can help improve patient outcomes and experiences.

We provide actionable genomic information for the moments that matter most in cancer care:

  • Can a patient avoid unnecessary surgery?
  • What is the optimal therapy?
  • How much time should we watch and wait between scans?
Discover our story
A Veracyte employee working in a lab.
A Veracyte employee smiling.

Join our team

Veracyte offers fulfilling career opportunities for curious, driven, and patient-oriented people who are inspired to find answers to some of the most challenging questions in medicine. Join us.

Working at Veracyte
View Job Openings

Making our tests available worldwide

Through our centralized CLIA lab-based approach in the US and our growing menu of distributed IVDs to serve global markets, we aim to transform cancer care for patients all over the world.

Enabling global access

ESG Report

Veracyte’s Environmental, Social and Governance (ESG) Report sets the foundation for our ESG performance and articulates our ambitions to build a more sustainable, equitable future.

ESG Report

Keep exploring

REFERENCES

  1. Company data on file.

  2. Cancer. World Health Organization. Published February 3, 2022. Accessed July 19, 2023. https://www.who.int/news-room/fact-sheets/detail/cancer

  3. Thyroid Cancer – Statistics. Cancer.Net. Accessed July 19, 2023. https://www.cancer.net/cancer-types/thyroid-cancer/statistics

  4. Bladder Cancer. International Agency for Research on Cancer. Accessed July 19, 2023. https://www.iarc.who.int/cancer-type/bladder-cancer/